Our product strategy reflects our evolution into a global innovation-led pharmaceutical organization. With a strong presence across key international markets, we deliver high-quality, science-driven products that advance patient care and address health challenges worldwide.
Built on decades of research excellence, operational strength, and a commitment to transform lives, our portfolio spans the therapeutic areas of respiratory, dermatology and oncology.
Our product offerings are anchored to meet the distinct needs of patients, healthcare providers, and global healthcare systems.
Branded Products
A key growth driver for our business is the Branded products category which contributes 60% of our revenue1. With a strong commercial presence across India, Asia Pacific (APAC), Europe, North America, Latin America (LATAM), and Middle East Africa (MEA), this portfolio spans a broad range of therapeutic areas, including respiratory, dermatology, oncology; and in India, cardiology, and diabetes. Our branded products are designed to address diverse patient needs, combining clinical relevance with strong physician and patient trust across markets.
Our flagship products include Ryaltris®, Ascoril®, and Alex® in Respiratory, TEVIMBRA® and Brukinsa®2 in Oncology in India, TelmaTM in Cardiology, Candid in Dermatology, and LIRAFIT™ for Diabetes. To know more about these products, click here.
Innovative Products
Moving up the value chain remains a central strategic priority. A strong focus on product development combined with strategic partnerships and in-licensing has strengthened our innovation-led portfolio. It targets complex health conditions and diseases where unmet medical needs remain significant. With a pipeline of globally recognized immuno-oncology assets, biologics, and precision medicines, we are building a differentiated, specialty-first model of care.
Our global portfolio of innovative products includes Ryaltris®, first of its kind fixed dose nasal spray marketed in 49 countries, and Winlevi®, a topical anti-acne cream, launched in the U.K., and which has also received market authorization across Europe.
Innovative Products
Moving up the value chain remains a central strategic priority. A strong focus on product development combined with strategic partnerships and in-licensing has strengthened our innovation-led portfolio. It targets complex health conditions and diseases where unmet medical needs remain significant. With a pipeline of globally recognized immuno-oncology assets, biologics, and precision medicines, we are building a differentiated, specialty-first model of care.
Our global portfolio of innovative products includes Ryaltris®, first of its kind fixed dose nasal spray marketed in 49 countries, and Winlevi®, a topical anti-acne cream, launched in the U.K., and which has also received market authorization across Europe.
Generics
Our Generics business primarily caters to North America (U.S. and Canada) and Europe markets. In the U.S. market alone, we have 213 generic products authorized for distribution3. We are focused on developing and supplying high-quality, affordable products with a strong emphasis underpinned by strict regulatory compliance.
We ensure accessibility by leveraging a robust network of sales representatives and maintaining a strong B2B and D2C connect, enabling our products to reach a wider audience.
With a total of more than 90 million prescriptions filled annually, we rank 14th in the U.S. market.
-
1 – As of FY25
-
2 – in-licensed
-
3 – As of Dec 15, 2025
Disclaimer :
You are advised to seek specific medical advice from a qualified medical practitioner for any diagnosis and / or treatment depending upon your specific condition.
This page contains only general information about Glenmark Products and the same shall in no way be construed as a substitute for medical advice. Glenmark uses reasonable efforts to update the information provided, some information may become obsolete over a period of time. Glenmark makes no claims or warranties as to the accuracy, completeness or use of the information nor accepts any liability to update the above information.